A biotech executive agreed to settle an SEC suit alleging he misappropriated about $3.2 million in corporate funds, including to buy a Beverly Hills mansion.
Anthony J. Cataldo carried out the scheme from November 2020 through October 2021 while serving as the CEO and chairman of an unnamed clinical-stage biopharmaceutical company, according to the Securities and Exchange Commission’s complaint filed Wednesday in the US District Court for the Central District of California.
Cataldo allegedly took $644,500 in unauthorized compensation payments and used nearly $2.6 million in company money as a down payment on a $9.15 million home.
In a proposed ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.